Behind-The-Counter Sale Works Without Regulation – Former FDA Counsel
This article was originally published in The Tan Sheet
Executive Summary
FDA's interest in establishing an official third class of drugs, as well as the OTC industry's concern about the idea, could be diminished because the agency already allows a path to behind-the-counter sales in new drug and switch applications, according to a former FDA chief counsel
You may also be interested in...
Behind-The-Counter Sale Is No Deterrent To Brand Loyalty – Survey
Behind-the-counter status does not diminish customers' loyalty to brand name nonprescription drugs, according to results of a nationwide survey
Behind-The-Counter Sale Is No Deterrent To Brand Loyalty – Survey
Behind-the-counter status does not diminish customers' loyalty to brand name nonprescription drugs, according to results of a nationwide survey
Behind-The-Counter Sale Is No Deterrent To Brand Loyalty – Survey
Behind-the-counter status does not diminish customers' loyalty to brand name nonprescription drugs, according to results of a nationwide survey